Why Cetero Research is the Choice for Small to Mid-Size Biopharmaceuticals
We’ll speed you to the next milestone while avoiding the bumps in the road. Because the faster you reach each milestone, the faster the compound can be advanced into later phases of clinical development.
Cetero is a particularly good choice for small to mid-size biopharmaceutical companies that don’t have extensive in-house resources, because we can put the whole package together for you: We have the services, staff and expertise to carry the most complex early phase studies from beginning to end, including consulting on the most efficient study strategy, planning and executing the study and medical writing and regulatory support. We understand the big picture, and then help you get every detail right. Our experience encompasses all early phase study designs across multiple therapeutic areas.
In fact, we focus exclusively on early phase studies, including full-service clinical pharmacology, bioanalytical and scientific affairs. And we have for nearly 30 years. We offer a complete package of specialized early phase services, as well as expert project management to put the pieces together in the most efficient manner.
Result: Our customers have made us the industry’s leading early phase CRO.
Everyone wants to move faster, but to do it without dramatically increasing risk takes the kind of experience and depth of early phase resources you’ll find only at Cetero:
First to Clinic. As early phase specialists, we have the capacity to recruit participants quickly in five different locations, and the flexibility to reallocate resources so you can get an early start on clinical pharmacology tests.
First to Proof-of-Concept. This combines multiple studies into one protocol, and overlaps activities to reduce the time from first-in-human to proof-of-concept from the typical 28 to 36 weeks to just 14 to 18 weeks.
If you’re in a hurry to reach your next milestone, get a fast start. Contact Cetero today.
